JP2022511550A5 - - Google Patents

Info

Publication number
JP2022511550A5
JP2022511550A5 JP2021532216A JP2021532216A JP2022511550A5 JP 2022511550 A5 JP2022511550 A5 JP 2022511550A5 JP 2021532216 A JP2021532216 A JP 2021532216A JP 2021532216 A JP2021532216 A JP 2021532216A JP 2022511550 A5 JP2022511550 A5 JP 2022511550A5
Authority
JP
Japan
Prior art keywords
rnai construct
construct according
pnpla3
modified nucleotide
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065481 external-priority patent/WO2020123508A2/en
Publication of JP2022511550A publication Critical patent/JP2022511550A/ja
Publication of JP2022511550A5 publication Critical patent/JP2022511550A5/ja
Priority to JP2024065950A priority Critical patent/JP2024105284A/ja
Pending legal-status Critical Current

Links

JP2021532216A 2018-12-10 2019-12-10 ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト Pending JP2022511550A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024065950A JP2024105284A (ja) 2018-12-10 2024-04-16 ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777714P 2018-12-10 2018-12-10
US62/777,714 2018-12-10
PCT/US2019/065481 WO2020123508A2 (en) 2018-12-10 2019-12-10 Rnai constructs for inhibiting pnpla3 expression and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065950A Division JP2024105284A (ja) 2018-12-10 2024-04-16 ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法

Publications (2)

Publication Number Publication Date
JP2022511550A JP2022511550A (ja) 2022-01-31
JP2022511550A5 true JP2022511550A5 (enExample) 2022-12-16

Family

ID=69024749

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532216A Pending JP2022511550A (ja) 2018-12-10 2019-12-10 ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト
JP2024065950A Pending JP2024105284A (ja) 2018-12-10 2024-04-16 ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024065950A Pending JP2024105284A (ja) 2018-12-10 2024-04-16 ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法

Country Status (22)

Country Link
US (2) US20220017906A1 (enExample)
EP (1) EP3894555A2 (enExample)
JP (2) JP2022511550A (enExample)
KR (1) KR20210102932A (enExample)
CN (2) CN121320339A (enExample)
AR (1) AR117297A1 (enExample)
AU (1) AU2019396419B2 (enExample)
BR (1) BR112021011061A2 (enExample)
CA (1) CA3121510A1 (enExample)
CL (1) CL2021001489A1 (enExample)
CO (1) CO2021008997A2 (enExample)
CR (1) CR20210371A (enExample)
EA (1) EA202191629A1 (enExample)
IL (1) IL283473A (enExample)
JO (1) JOP20210142A1 (enExample)
MX (2) MX2021006784A (enExample)
PE (1) PE20211225A1 (enExample)
PH (1) PH12021551326A1 (enExample)
SG (1) SG11202105711SA (enExample)
TW (1) TW202039843A (enExample)
UY (1) UY38503A (enExample)
WO (1) WO2020123508A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115927335A (zh) 2015-04-13 2023-04-07 阿尔尼拉姆医药品有限公司 类血管生成素3（ANGPTL3）iRNA组合物及其使用方法
UY38003A (es) * 2017-12-12 2019-06-28 Amgen Inc Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
CA3209418A1 (en) * 2021-04-14 2022-10-20 Utsav SAXENA Compositions and methods for modulating pnpla3 expression
EP4347823A1 (en) * 2021-06-02 2024-04-10 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US20250243491A1 (en) * 2021-09-01 2025-07-31 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
AU2023313030A1 (en) * 2022-07-27 2025-01-09 E-Therapeutics Plc Nucleic acid compounds
WO2024120412A1 (en) * 2022-12-07 2024-06-13 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of patatin-like phospholipase domain-containing 3 (pnpla3)
AU2023408479A1 (en) * 2022-12-19 2025-05-01 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar)
EP4665852A1 (en) * 2023-02-14 2025-12-24 Basecure Therapeutics Modified double stranded rna agents
WO2024182446A2 (en) * 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
CN121335980A (zh) * 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
AU747597B2 (en) 1998-07-20 2002-05-16 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
CA2685127C (en) 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP3564374A1 (en) 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
CA2976445A1 (en) * 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2017048620A1 (en) * 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
US10036024B2 (en) * 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
JP2020522510A (ja) * 2017-06-02 2020-07-30 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド組成物及びその使用方法
CA3065523A1 (en) * 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
UY38003A (es) * 2017-12-12 2019-06-28 Amgen Inc Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas

Similar Documents

Publication Publication Date Title
JP2022511550A5 (enExample)
JP2021506238A5 (enExample)
US9410154B2 (en) HBV treatment
JP2022078069A (ja) 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物
JP2024105284A5 (enExample)
TW201920227A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
JP2011511636A5 (enExample)
JP2011505833A5 (enExample)
JP2016513976A5 (enExample)
JP2016522674A5 (enExample)
JP2015523853A5 (enExample)
EA035433B1 (ru) Модуляторы фактора в комплемента
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
JP2023539341A (ja) Ｄｕｘ４阻害剤およびその使用方法
CA3238865A1 (en) Composition and methods for inhibiting expression of angiotensinogen (agt) protein
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
CN103380215A (zh) 包含锁定核苷酸的微rna抑制剂
JP2017528441A5 (enExample)
JP2024512635A5 (enExample)
JP2022534402A5 (enExample)
JP6987157B2 (ja) 男性型脱毛標的遺伝子の発現を抑制する非対称ｓｉＲＮＡ
CN115916978A (zh) 寡核苷酸
JP2023553610A5 (enExample)
US8987227B2 (en) Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease